Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Mistry

Showing results (131-140 of 237) with videos related to

Pageof 24
Sort By:
Nature Communications|September 26, 2025
Synaptic vesicle endocytosis deficits underlie cognitive dysfunction in mouse models of GBA-linked Parkinson's disease and dementia with Lewy bodiesD J Vidyadhara, David Bäckström, Risha Chakraborty, et al.
Computational Brain & Behavior|July 16, 2026
Bayesian Graphical Modeling with the Circular Drift Diffusion ModelManuel Villarreal, Adriana F Chávez De la Peña, Percy K Mistry, et al.
Journal of Inherited Metabolic Disease|March 30, 2011
Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapySarah Michelman Lo, Jun Liu, F Chen, et al.
Lancet (London, England)|September 12, 2000
Oxidative-phosphorylation defects in liver of patients with Wilson's diseaseM Gu, J M Cooper, P Butler, et al.
Molecular Genetics and Metabolism Reports|September 6, 2021
Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher diseaseNathaniel Kleytman, Jiapeng Ruan, Audrey Ruan, et al.
Journal of Clinical Medicine|May 13, 2023
The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). <i>J. Clin. Med.</i> 2022, <i>11</i>, 5158Pramod K Mistry, Priya S Kishnani, Manisha Balwani, et al.
British Journal of Clinical Pharmacology|January 1, 1988
The in vitro 5-lipoxygenase and cyclo-oxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase in vivo in human skinR M Barr, A K Black, P M Dowd, et al.
British Journal of Clinical Pharmacology|December 1, 1986
Topical steroid treatment reduces arachidonic acid and leukotriene B4 in lesional skin of psoriasisE Wong, R M Barr, F M Cunningham, et al.
Blood Cells, Molecules & Diseases|December 23, 2016
Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher diseaseVagishwari Murugesan, Jun Liu, Ruhua Yang, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|January 24, 2002
Cloning of human agmatinase. An alternate path for polyamine synthesis induced in liver by hepatitis B virusSanjay K Mistry, Tim J Burwell, Rebecca M Chambers, et al.
Pageof 24

Showing results (131-140 of 237) with videos related to

Sort By:
Pageof 24
Nature Communications|September 26, 2025
Synaptic vesicle endocytosis deficits underlie cognitive dysfunction in mouse models of GBA-linked Parkinson's disease and dementia with Lewy bodiesD J Vidyadhara, David Bäckström, Risha Chakraborty, et al.
Computational Brain & Behavior|July 16, 2026
Bayesian Graphical Modeling with the Circular Drift Diffusion ModelManuel Villarreal, Adriana F Chávez De la Peña, Percy K Mistry, et al.
Journal of Inherited Metabolic Disease|March 30, 2011
Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapySarah Michelman Lo, Jun Liu, F Chen, et al.
Lancet (London, England)|September 12, 2000
Oxidative-phosphorylation defects in liver of patients with Wilson's diseaseM Gu, J M Cooper, P Butler, et al.
Molecular Genetics and Metabolism Reports|September 6, 2021
Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher diseaseNathaniel Kleytman, Jiapeng Ruan, Audrey Ruan, et al.
Journal of Clinical Medicine|May 13, 2023
The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). <i>J. Clin. Med.</i> 2022, <i>11</i>, 5158Pramod K Mistry, Priya S Kishnani, Manisha Balwani, et al.
British Journal of Clinical Pharmacology|January 1, 1988
The in vitro 5-lipoxygenase and cyclo-oxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase in vivo in human skinR M Barr, A K Black, P M Dowd, et al.
British Journal of Clinical Pharmacology|December 1, 1986
Topical steroid treatment reduces arachidonic acid and leukotriene B4 in lesional skin of psoriasisE Wong, R M Barr, F M Cunningham, et al.
Blood Cells, Molecules & Diseases|December 23, 2016
Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher diseaseVagishwari Murugesan, Jun Liu, Ruhua Yang, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|January 24, 2002
Cloning of human agmatinase. An alternate path for polyamine synthesis induced in liver by hepatitis B virusSanjay K Mistry, Tim J Burwell, Rebecca M Chambers, et al.
Pageof 24